Drugs · acquisition-cost intelligence
Diazepam
· ingredient diazepam· DIAZEPAM 5 mg/5mL; DIAZEPAM 5 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.55328
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other diazepam products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| diazepam | $0.02861 | −$0.52470 |
| Diazepam Intensol | $0.99686 | +$0.44360 |
| Diazepam | $191.47 | +$190.92 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 48% · Step therapy 0% · Quantity limit 86% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.